Kala Pharmaceuticals, Inc. (KALA) |
|
15.11 -0.46 (-2.95%)
|
03-27 16:00 |
|
Open: |
15.95 |
Pre. Close: |
15.57 |
|
High:
|
18.35 |
Low:
|
13.9 |
|
Volume:
|
1,013,291 |
Market Cap:
|
31(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:20:34 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 21.46 One year: 28.03 |
| Support: |
Support1: 9.27 Support2: 7.71 |
| Resistance: |
Resistance1: 18.37 Resistance2: 24 |
| Pivot: |
16.17  |
| Moving Average: |
MA(5): 14.92 MA(20): 15.57
MA(100): 13.02 MA(250): 17.89 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 27.1 %D(3): 30.9 |
| RSI: |
RSI(14): 49.5 |
| 52-week: |
High: 69.5 Low: 0.32 |
| Average Vol(K): |
3-Month: 2,082 (K) 10-Days: 405 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KALA ] has closed above bottom band by 38.7%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
18.37 - 18.47 |
18.47 - 18.55 |
|
Low:
|
13.72 - 13.81 |
13.81 - 13.88 |
|
Close:
|
14.96 - 15.12 |
15.12 - 15.25 |
|
Company Description |
|
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. |
Headline News |
Mon, 27 Mar 2023
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan - Nasdaq
Mon, 27 Mar 2023
KALA PHARMACEUTICALS, INC. : Other Events (form 8-K) - Marketscreener.com
Mon, 27 Mar 2023
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED - Yahoo Finance
Thu, 23 Mar 2023
Can Kala Pharmaceuticals Inc (KALA) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Wed, 22 Mar 2023
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals - Yahoo Finance
Wed, 08 Mar 2023
Kala Pharmaceuticals Inc (KALA) is down 8.56% Wednesday In Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
1.19e+006 (%) |
|
% Held by Institutions
|
6.9 (%) |
|
Shares Short
|
101 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.754e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-1.92 |
|
EPS Est Next Year
|
-1.87 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
708.5 |
|
Return on Equity (ttm)
|
-44 |
|
Qtrly Rev. Growth
|
5.75e+006 |
|
Gross Profit (p.s.)
|
-90.85 |
|
Sales Per Share
|
-276.81 |
|
EBITDA (p.s.)
|
7.51579e+006 |
|
Qtrly Earnings Growth
|
-2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-93 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.06 |
|
Price to Cash Flow
|
-15.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
236300 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
